Medtronic plc (NYSE:MDT ) Q1 2026 Earnings Conference Call August 19, 2025 8:00 AM ET Company Participants Geoffrey Straub Martha - Chairman of the Board & CEO Michael Marinaro - Executive VP & President of Medical Surgical Portfolio and Americas Que Thanh Dallara - Executive VP & President Diabetes Operating Unit Ryan Weispfenning - VP & Head of Investor Relations Thierry Pieton - Executive VP & CFO Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Joanne Karen Wuensch - Citigroup Inc. Exchange Research Joshua Thomas Jennings - TD Cowen, Research Division Lawrence H. Biegelsen - Wells Fargo Securities, LLC, Research Division Matthew Oliver O'Brien - Piper Sandler & Co., Research Division Matthew Stephan Miksic - Barclays Bank PLC, Research Division Michael Holden Kratky - Leerink Partners LLC, Research Division Robert Justin Marcus - JPMorgan Chase & Co, Research Division Travis Lee Steed - BofA Securities, Research Division Ryan Weispfenning Hello, everyone, and thanks for joining us today for our fiscal '26 first quarter video earnings webcast.
Medtronic tops on Q1 earnings and revenues, raises full-year EPS outlook, but shares dip on board changes.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.23 per share a year ago.
Medtronic appoints two new board directors following talks with activist investor Elliott Investment Management.
Medical-device maker Medtronic raised its fiscal 2026 profit forecast on Tuesday and said it expects a smaller-than-expected impact from the tariffs proposed by U.S. President Donald Trump.
The medical-device maker also plans to form committees focused on M&A and other growth areas.
Medtronic (NYSE:MDT) will report earnings on Tuesday, August 19, 2025. Over the last five years, the stock's next-day move following results has been highly unpredictable: it posted a positive one-day return in 50% of instances (median gain of 2.5%) and a negative one-day return in the other 50% (median loss of -3.8%).
In the closing of the recent trading day, Medtronic (MDT) stood at $91.98, denoting a -1% move from the preceding trading day.
Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2025.
Medtronic trades at a notable discount to peers as Q1 earnings loom, but rising costs and tariffs could test its resilience.